The Global Idiopathic Pulmonary Fibrosis (IPF) market held a market value of USD 2,073.9 Million in 2021 and is forecasted to reach USD 4,298.8 Million by the year 2030. The market is anticipated to register a CAGR of 9.4% over the projected period.
Idiopathic Pulmonary Fibrosis (IPF) is one of the most common types of pulmonary fibrosis, which causes scarring or fibrosis in the lungs. This makes it difficult for a person to breath. Growing geriatric population, increase in smokers’ population, and favourable support through funding for the pulmonary fibrosis research is anticipated to boost the market growth. Despite the driving factors, high treatment cost are expected to hinder the market growth during the forecast period.
Growing geriatric population
Geriatric population is more likely to suffer from idiopathic pulmonary fibrosis (IPF), which is likely to boost the market growth. According to the WHO, the geriatric population is expected to nearly double from 12% to 22% between 2015 and 2050. Also, according to Medscape, as of July 2021, approximately two third of IPF patients are above the age of 60 years. It also stated that in the U.S., the incidence rate of IPF in people aged 18 to 34 years is around 0.4-1.2 cases per 100,000 people and in people aged 75 years or older is ranged between 27.1-76.4 cases per 100,000 people. Therefore, growing geriatric population is expected to fuel the market growth over the projected period.
Increase in smokers’ population
According to BioNews, Inc., as of October 2021, current smokers are at higher risk of IPF as compared to former smokers. The exact cause of IPF is unknown, however smoking cigarettes is most probably the most well-established risk factor for IPF. The source also stated that, at the end of 2016, in a study, 27.2% of IPF patients were current smokers, 23.2% were former smokers, and 49.6% were never-smokers. Therefore, the growing smokers’ population is expected to boost the market growth.
The Global Idiopathic Pulmonary Fibrosis (IPF) market is segmented based on therapy.
The Esbriet (Pirfenidone) segment is expected to account for the highest share of 30% in the U.S. market in 2021. This is because it has received the label of “conditional recommendation for IPF treatment”. The tipelukast segment is anticipated to grow at a CAGR of 8.7% in the UK market, owing to the growing number of players involved in the development of tipelukast.
Based on region, the Global Idiopathic Pulmonary Fibrosis (IPF) market is divided into the U.S., EU5, and Japan.
The U.S. is estimated to account for the largest market share of over 60% in 2021 owing to the growing research activities for IPF and presence of a significant infrastructure for the development of innovative therapies.
EU5 is further divided into the UK, France, Germany, Spain, and Italy. The UK is expected to hold an opportunity of USD 232.2 million during 2021 to 2030. This is owing to the increasing prevalence of idiopathic pulmonary fibrosis in the country.
The prevalent population of IPF is usually based on the severity, gender, and age. In Japan, the prevalent population was 18.849. Similarly, in the U.S., the prevalent population of IPF, based on severity was 74,230 in 2021 and 1,27,397 in 2030 based on radiological markers of disease severity and 43,973 in 2021, based on the composite measures of disease severity.
Currently marketed products include Esbriet (Pirfenidone) by Genentech, Inc. and Ofev by Boehringer Ingelheim Pharma GmbH & Co. KG. In March 2020, Esbriet received U.S. FDA’s Breakthrough Therapy Designation for adults suffering from unclassifiable interstitial lung disease. Similarly, in March 2020, Ofev by Boehringer Ingelheim GmbH received U.S. FDA approval for use as a first treatment for people suffering from chronic fibrosing interstitial lung diseases (ILDs). Also, in October 2021, Ofev was recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of adult patients suffering from chronic fibrosis ILD with a progressive phenotype, PF-ILD.
Idiopathic Pulmonary Fibrosis (IPF) is one of the most common types of pulmonary fibrosis, which causes scarring or fibrosis in the lungs. This makes it difficult for a person to breath. Growing geriatric population, increase in smokers’ population, and favourable support through funding for the pulmonary fibrosis research is anticipated to boost the market growth. Despite the driving factors, high treatment cost are expected to hinder the market growth during the forecast period.
Growth Influencers:
Growing geriatric population
Geriatric population is more likely to suffer from idiopathic pulmonary fibrosis (IPF), which is likely to boost the market growth. According to the WHO, the geriatric population is expected to nearly double from 12% to 22% between 2015 and 2050. Also, according to Medscape, as of July 2021, approximately two third of IPF patients are above the age of 60 years. It also stated that in the U.S., the incidence rate of IPF in people aged 18 to 34 years is around 0.4-1.2 cases per 100,000 people and in people aged 75 years or older is ranged between 27.1-76.4 cases per 100,000 people. Therefore, growing geriatric population is expected to fuel the market growth over the projected period.
Increase in smokers’ population
According to BioNews, Inc., as of October 2021, current smokers are at higher risk of IPF as compared to former smokers. The exact cause of IPF is unknown, however smoking cigarettes is most probably the most well-established risk factor for IPF. The source also stated that, at the end of 2016, in a study, 27.2% of IPF patients were current smokers, 23.2% were former smokers, and 49.6% were never-smokers. Therefore, the growing smokers’ population is expected to boost the market growth.
Segments Overview:
The Global Idiopathic Pulmonary Fibrosis (IPF) market is segmented based on therapy.
By Therapy
- Esbriet (Pirfenidone)
- Ofev (Nintedanib)
- Tipelukast
- Pamrevlumab
- KD025
- PRM 151
- GKT831
- Other IPF Therapy
The Esbriet (Pirfenidone) segment is expected to account for the highest share of 30% in the U.S. market in 2021. This is because it has received the label of “conditional recommendation for IPF treatment”. The tipelukast segment is anticipated to grow at a CAGR of 8.7% in the UK market, owing to the growing number of players involved in the development of tipelukast.
Regional Overview
Based on region, the Global Idiopathic Pulmonary Fibrosis (IPF) market is divided into the U.S., EU5, and Japan.
The U.S. is estimated to account for the largest market share of over 60% in 2021 owing to the growing research activities for IPF and presence of a significant infrastructure for the development of innovative therapies.
EU5 is further divided into the UK, France, Germany, Spain, and Italy. The UK is expected to hold an opportunity of USD 232.2 million during 2021 to 2030. This is owing to the increasing prevalence of idiopathic pulmonary fibrosis in the country.
The prevalent population of IPF is usually based on the severity, gender, and age. In Japan, the prevalent population was 18.849. Similarly, in the U.S., the prevalent population of IPF, based on severity was 74,230 in 2021 and 1,27,397 in 2030 based on radiological markers of disease severity and 43,973 in 2021, based on the composite measures of disease severity.
Competitive Landscape
Currently marketed products include Esbriet (Pirfenidone) by Genentech, Inc. and Ofev by Boehringer Ingelheim Pharma GmbH & Co. KG. In March 2020, Esbriet received U.S. FDA’s Breakthrough Therapy Designation for adults suffering from unclassifiable interstitial lung disease. Similarly, in March 2020, Ofev by Boehringer Ingelheim GmbH received U.S. FDA approval for use as a first treatment for people suffering from chronic fibrosing interstitial lung diseases (ILDs). Also, in October 2021, Ofev was recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of adult patients suffering from chronic fibrosis ILD with a progressive phenotype, PF-ILD.
The Global Idiopathic Pulmonary Fibrosis (IPF) market report provides insights on the below pointers:
- Market Penetration: Provides comprehensive information on the market offered by the prominent players
- Market Development: The report offers detailed information about lucrative emerging markets and analyzes penetration across mature segments of the markets
- Market Diversification: Provides in-depth information about untapped geographies, recent developments, and investments
- Competitive Landscape Assessment: Mergers & acquisitions, certifications, product launches in the Global Idiopathic Pulmonary Fibrosis (IPF) market have been provided in this research report. In addition, the report also emphasizes the SWOT analysis of the leading players.
- Product Development & Innovation: The report provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
- Current Treatment Practices: ATS//ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis (An Update of 2011 Clinical Practice Guideline)
- Organizations contributing towards IPF: Pulmonary Fibrosis Foundation (PFF), National Organization for Rare Disorder, Second Wind Lung Transplant Association, Inc., Other Organizations
- Case Reports: Idiopathic Pulmonary Fibrosis: A Case Discussion in the US, Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: A Case Report of Europe, Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis - A Japanese Case Report
- Marketed Products- Esbriet (Pirfenidone): Genentech, Inc. (Drug Description, Regulatory Milestones, Advantages & Disadvantages, Safety and Efficacy, Side Effects of Esbriet, Product Profile); Ofev: Boehringer Ingelheim Pharma GmbH and Co. Kg
- Emerging Therapies: Tipelukast: MediciNova (Drug Description, Clinical Development, Clinical Trial Information, Primary Outcomes, Secondary Outcomes, Product Profile, Pamrevlumab: FibroGen, KD025: Kadmon Corporation, LLC, Promedior: PRM-151); GKT831: Genkyotex
- Other Promising Candidates: CC-90001: Celgene Corporation, LT-1001: Beijing Tide Pharmaceutical, LT-1002: ChongKun DangPharmaceutical, BG00011: BiogenInc, PBI4050: ProMetic LifeSciences, TD139: Galecto Biotech, VAY736: Novartis
The Global Idiopathic Pulmonary Fibrosis (IPF) market report answers questions such as:
- What is the market size and forecast of the Global Idiopathic Pulmonary Fibrosis (IPF) Market?
- What are the inhibiting factors and impact of COVID-19 on the Global Idiopathic Pulmonary Fibrosis (IPF) Market during the assessment period?
- Which are the products/segments/applications/areas to invest in over the assessment period in the Global Idiopathic Pulmonary Fibrosis (IPF) Market?
- What is the competitive strategic window for opportunities in the Global Idiopathic Pulmonary Fibrosis (IPF) Market?
- What are the technology trends and regulatory frameworks in the Global Idiopathic Pulmonary Fibrosis (IPF) Market?
- What is the market share of the leading players in the Global Idiopathic Pulmonary Fibrosis (IPF) Market?
- What modes and strategic moves are considered favorable for entering the Global Idiopathic Pulmonary Fibrosis (IPF) Market?
- What are the unmet needs in IPF Market?
Table of Contents
1. Key Insights??
2. Idiopathic Pulmonary Fibrosis Market Overview at a Glance?
3. Market Overview: Idiopathic Pulmonary Fibrosis (IPF)?
4. Epidemiology and Patient Population?
5. Current Treatment Practices?
7. Organizations contributing toward IPF?
8. KOL’s Views: Idiopathic Pulmonary Fibrosis?
9. Case Reports?
10. Marketed Products?
11. Emerging Therapies?
12. Other Promising Candidates?
13. Idiopathic Pulmonary Fibrosis: Market Analysis?
14. Market Size of Idiopathic Pulmonary Fibrosis by Country?
17. Appendix?
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- InterMuneInc.
- BoehringerIngelheimPharma GmbHand Co. KG
- MediciNova
- FibroGen
- KadmonCorporation,LLCs
- Promedior,Inc.
- Genkyotex
- CelgeneCorporation
- Beijing Tide Pharmaceutical
- ChongKun DangPharmaceutical
- BiogenInc.
- ProMetic LifeSciences
- GalectoBiotech
- Novartis
- TaihoPharmaceutical
- Nitto Denko Corporation
- Trevi Therapeutics
- Respivant Sciences
- Merck andCo.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 191 |
| Published | January 2022 |
| Forecast Period | 2021 - 2030 |
| Estimated Market Value ( USD | $ 2073.9 Million |
| Forecasted Market Value ( USD | $ 4298.8 Million |
| Compound Annual Growth Rate | 9.4% |
| Regions Covered | Global |
